QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-hold-on-axonics

Needham analyst Mike Matson reiterates Axonics (NASDAQ:AXNX) with a Hold.

 needham-reiterates-hold-on-axonics

Needham analyst Mike Matson reiterates Axonics (NASDAQ:AXNX) with a Hold.

 axonics-q1-eps-038-misses-008-estimate-sales-9141m-beat-8959m-estimate

Axonics (NASDAQ:AXNX) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.08) by ...

 fda-classifies-boston-scientifics-recall-for-device-to-stop-blood-flow-as-most-serious

Boston Scientific announces a Class I recall of Obsidio Embolic due to high-risk implications for lower GI bleeding embolizatio...

Core News & Articles

Axonics, Inc. (NASDAQ:AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston...

Core News & Articles

Today, the PTAB invalidated 10 of the 15 challenged claims in Medtronic's ‘314 patent and declined to invalidate the challe...

Core News & Articles

Axonics, Inc. (NASDAQ:AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. Inte...

 rbc-capital-reiterates-sector-perform-on-axonics-maintains-71-price-target

RBC Capital analyst Shagun Singh reiterates Axonics (NASDAQ:AXNX) with a Sector Perform and maintains $71 price target.

 axonics-q4-eps-013-beats-006-estimate-sales-10973m-beat-10733m-estimate

Axonics (NASDAQ:AXNX) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.06 by 116....

 why-medical-devices-giant-boston-scientific-shares-are-rising-today

Boston Scientific shares surge in premarket trading following strong Q4 results, beating revenue estimates, amid positive outlo...

 needham-downgrades-axonics-to-hold

Needham analyst Mike Matson downgrades Axonics (NASDAQ:AXNX) from Buy to Hold.

 truist-securities-downgrades-axonics-to-hold-lowers-price-target-to-71

Truist Securities analyst David Rescott downgrades Axonics (NASDAQ:AXNX) from Buy to Hold and lowers the price target from $...

 truist-securities-downgrades-axonics-to-hold-lowers-price-target-to-71

Truist Securities analyst David Rescott downgrades Axonics (NASDAQ:AXNX) from Buy to Hold and lowers the price target from $...

 cl-king-downgrades-axonics-to-neutral

CL King analyst Kristen Stewart downgrades Axonics (NASDAQ:AXNX) from Buy to Neutral.

 piper-sandler-downgrades-axonics-to-neutral-lowers-price-target-to-71

Piper Sandler analyst Adam Maeder downgrades Axonics (NASDAQ:AXNX) from Overweight to Neutral and lowers the price target fr...

 leerink-partners-downgrades-axonics-to-market-perform-announces-71-price-target

Leerink Partners analyst Mike Kratky downgrades Axonics (NASDAQ:AXNX) from Outperform to Market Perform and announces $71 pr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION